Announcement no. 24

BioPorto completes directed share issue

On August 25, 2009, the Board of Directors of BioPorto A/S made use of its authorization under § 15a of the Company Articles to make a directed share issue directed to a limited number of shareholders. The completion of the emission has today been approved by the Board.

The directed issue was oversubscribed by more than 50%. In consequence, the Board has determined how the shares are to be allocated, a total 3,830,000 new shares each with nominal value DKK 3.00, corresponding to a total nominal value of DKK 11,490,000.

The subscription price was set at DKK 3.97 per share, being the weighted average of the trading price of BioPorto A/S shares as noted on the NASDAQ OMX Copenhagen stock exchange over the 10 days of transaction preceding the Board’s decision on August 25, 2009. The issue thus provides BioPorto with gross proceeds of approximately DKK 15.2 million, from which transaction costs of DKK 0.5 million have to be subtracted to yield net proceeds of DKK 14.7 million.

The new shares, comprising the maximum number of shares offered, correspond to just under 10% of Bioporto’s registered share capital before the capital increase, so that the issue is exempt from the requirement to issue a prospectus.

The new shares carry the same rights as existing shares, so that it should be especially noted that the new shares are freely negotiable. The new shares will be eligible for dividends as from the moment when they have been fully paid for and issued. The capital increase is expected to be registered with The Danish Commerce and Companies Agency on October 1, 2009.

The new shares are expected to be admitted for listing on NASDAQ OMX Copenhagen on October 6, 2009. After registration of the 3,830,000 new shares each with nominal value DKK 3.00, BioPorto’s total nominal share capital will amount to DKK 126,397,872, consisting of 42,132,624 shares each with nominal value DKK 3.00.

Use of proceeds

The capital increase will secure the Company’s capital resources, create the best foundation for finishing and marketing the Company’s new homogeneous NGAL test, and secure the Company’s very considerable patent rights, supporting the Company’s running costs and sources of income. The capital increase will thus minimize the Company’s financial risks and allow increased flexibility in the current licensing negotiations. Assuming the current level of Company activity, the additional capital will secure coverage of running costs into 2011.

Trading by the Board of Directors and Management

In the directed share issue, the Company’s Board of Directors and Management have subscribed a total of 153,000 shares, corresponding to 4% of the shares on offer. The share subscriptions are distributed as follows:

Thea Olesen, CEO

Christina Tønnesen, Investor Relations

Telephone +45 45 29 00 00, mail investor@bioporto.com